In the quest to outshine the broader market, stock pickers diligently seek out stocks with the potential for superior performance. Making the right choices can significantly elevate your wealth.
As of close of business last night, X4 Pharmaceuticals Inc’s stock clocked out at $0.34, up 7.42% from its previous closing price of $0.32. In other words, the price has increased by $7.42 from its previous closing price. On the day, 1.42 million shares were traded. XFOR stock price reached its highest trading level at $0.3498 during the session, while it also had its lowest trading level at $0.32.
Ratios:
To gain a deeper understanding of XFOR’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 4.80 and its Current Ratio is at 4.89. In the meantime, Its Debt-to-Equity ratio is 1.31 whereas as Long-Term Debt/Eq ratio is at 1.29.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, B. Riley Securities on December 12, 2023, Downgraded its rating to Neutral and sets its target price to $1 from $3 previously.
On December 22, 2022, Cantor Fitzgerald started tracking the stock assigning a Overweight rating and target price of $3.Cantor Fitzgerald initiated its Overweight rating on December 22, 2022, with a $3 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on May 17 ’24 when Baldry Mark bought 21,646 shares for $0.68 per share. The transaction valued at 14,654 led to the insider holds 115,769 shares of the business.
Baldry Mark bought 13,404 shares of XFOR for $4,598 on Nov 15 ’24. The Chief Commercial Officer now owns 129,173 shares after completing the transaction at $0.34 per share. On Jan 24 ’25, another insider, Ragan Paula, who serves as the President and CEO of the company, sold 76,473 shares for $0.45 each. As a result, the insider received 34,719 and left with 1,087,386 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, XFOR now has a Market Capitalization of 58002692 and an Enterprise Value of 1228854. For the stock, the TTM Price-to-Sale (P/S) ratio is 51.79 while its Price-to-Book (P/B) ratio in mrq is 0.96. Its current Enterprise Value per Revenue stands at 1.094 whereas that against EBITDA is -0.009.
Stock Price History:
The Beta on a monthly basis for XFOR is 0.49, which has changed by -0.63163596 over the last 52 weeks, in comparison to a change of 0.09506309 over the same period for the S&P500. Over the past 52 weeks, XFOR has reached a high of $1.60, while it has fallen to a 52-week low of $0.26. The 50-Day Moving Average of the stock is -32.46%, while the 200-Day Moving Average is calculated to be -45.78%.
Shares Statistics:
It appears that XFOR traded 3.81M shares on average per day over the past three months and 1512210 shares per day over the past ten days. A total of 168.51M shares are outstanding, with a floating share count of 112.96M. Insiders hold about 33.77% of the company’s shares, while institutions hold 31.30% stake in the company. Shares short for XFOR as of 1740700800 were 9480584 with a Short Ratio of 2.49, compared to 1738281600 on 16606425. Therefore, it implies a Short% of Shares Outstanding of 9480584 and a Short% of Float of 5.609999999999999.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
